BTIG analyst Ryan Zimmerman maintained a Hold rating on AxoGen (AXGN) yesterday. The company’s shares closed last Monday at $21.19.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 34.7% and a 68.7% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Zimmer Biomet Holdings, and Staar Surgical Company.
AxoGen has an analyst consensus of Moderate Buy, with a price target consensus of $22.00.
See today’s analyst top recommended stocks >>
AxoGen’s market cap is currently $838.8M and has a P/E ratio of -31.30. The company has a Price to Book ratio of 6.68.
Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AXGN in relation to earlier this year. Most recently, in December 2020, Karen Zaderej, the CEO of AXGN bought 19,375 shares for a total of $93,194.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.